Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.
Michael K. K. Wong, MD, PhD
Advertisement
Articles by Michael K. K. Wong, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5